EQS-News: MorphoSys AG / Key word: Miscellaneous
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
11.05.2023 / 18:39. | May 11, 2023
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 11, 2023 M.
Monjuvi U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline
03.05.2023 - EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim Statement MorphoSys AG Reports First Quarter 2023 Financial Results 03.05.2023 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release .